Despite inducing a significant increase in CD8+ T cell infiltration in the tumour, the combined olaparib and AZD1775 treatment at lower doses led to a significant reduction of PD-L1 expression on the AT3 tumours (Fig. 2d) which could explain the striking lack of response to anti-PD-1 treatment. This evidence concerns the gene CD8A and neoplasm.